MNG913
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.523
- INFLAMMATORY_RESPONSE+0.272
- KRAS_SIGNALING_DN+0.197
- SPERMATOGENESIS+0.185
- OXIDATIVE_PHOSPHORYLATION+0.172
- IL6_JAK_STAT3_SIGNALING+0.166
- INTERFERON_GAMMA_RESPONSE+0.147
- PANCREAS_BETA_CELLS+0.129
- E2F_TARGETS+0.126
- MYC_TARGETS_V2+0.117
Top 10 suppressed
- TGF_BETA_SIGNALING-0.501
- PROTEIN_SECRETION-0.473
- UV_RESPONSE_DN-0.447
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.442
- WNT_BETA_CATENIN_SIGNALING-0.434
- UNFOLDED_PROTEIN_RESPONSE-0.345
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.330
- HEDGEHOG_SIGNALING-0.328
- HYPOXIA-0.299
- PEROXISOME-0.297
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR23303738 | — | — | 0.798 |
| 2 | TCGA-56-A49D-01A-11R-A24H-07 | — | cohortSQ1 | 0.782 |
| 3 | SRR25617831 | — | D | 0.773 |
| 4 | 5e2bb136-9a8b-4481-9394-d7eff1793f97 | — | — | 0.757 |
| 5 | SRR2932833 | — | — | 0.754 |
| 6 | TCGA-GM-A2DO-01A-11R-A18M-07 | — | D | 0.750 |
| 7 | EOL1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.744 |
| 8 | TCGA-MZ-A5BI-01A-31R-A34R-07 | — | — | 0.742 |
| 9 | EPT0776 | EPN | EPN Tumor | 0.734 |
| 10 | SRR5903553 | — | cohortA1 | 0.733 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.523 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.272 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.197 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.185 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.172 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.166 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.147 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.129 | Cobimetinib | — uncovered |
| E2F_TARGETS | 0.126 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.117 | Idelalisib | — uncovered |
| COMPLEMENT | 0.090 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.058 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.040 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.010 | Inavolisib | — uncovered |